Page 18 - 《中国药房》2025年11期
P. 18
fluence of hepatic impairment on everolimus pharmacoki‐ [60] OLIVEIRA M,RUGO H S,HOWELL S J,et al. Capiva-
netics:implications for dose adjustment[J]. Clin Pharma‐ sertib and fulvestrant for patients with hormone receptor-
col Ther,2001,70(5):425-430. positive,HER2-negative advanced breast cancer (CAPI‐
[49] ROYER B,KADERBHAÏ C G,SCHMITT A. Pharmaco‐ tello-291):patient-reported outcomes from a phase 3,ran‐
kinetics and pharmacodynamic of alpelisib[J]. Clin Phar‐ domised,double-blind,placebo-controlled trial[J]. Lancet
macokinet,2023,62(1):45-53. Oncol,2024,25(9):1231-1244.
[50] 中国抗癌协会肿瘤药物临床研究专业委员会,国家肿瘤 [61] XU K Y,SHAMEEM R,WU S H. Risk of hyperglycemia
质控中心乳腺癌专家委员会,中国抗癌协会肿瘤病理专 attributable to everolimus in cancer patients:a meta-
业委员会,等 . PI3K/AKT/mTOR 信号通路抑制剂治疗 analysis[J]. Acta Oncol. 2016,55(9/10):1196-1203.
乳腺癌临床应用专家共识[J]. 中华肿瘤杂志,2022,44 [62] FDA. Drug development and drug interactions table of
(7):673-692. substrates,inhibitors and inducers[EB/OL]. [2024-11-08].
[51] DE MORAES F C A,SANO V K T,PEREIRA C R M, https://www.fda.gov/drugs/drug-interactions-labeling/drug-
et al. Treatment-related adverse events in patients with ad‐ development-and-drug-interactions-table-substrates-inhibi-
vanced breast cancer receiving adjuvant AKT inhibitors:a tors-and-inducers.
meta-analysis of randomized controlled trials[J]. Eur J [63] GEBBIA V,BELLAVIA G,FERRAÙ F,et al. Adherence,
Clin Pharmacol,2024,80(9):1373-1385. compliance and persistence to oral antineoplastic therapy:
[52] 周慧,海广范,张涛,等 . 癌症治疗中 PI3K/AKT/mTOR a review focused on chemotherapeutic and biologic agents
通路及靶向抑制剂研究进展[J]. 中国药业,2023,32(5): [J]. Expert Opin Drug Saf,2012,11(Supp. 1):S49-S59.
127-135. [64] 李朋梅,张明,张相林. 依维莫司的药动学影响因素及治
[53] 郑范丽,郑亚楠,黄莉莉,等 . PI3Kδ 抑制剂在 B 细胞淋 疗药物监测研究进展[J]. 中国药房,2013,24(46):4383-
巴瘤中的应用情况[J]. 中国现代应用药学,2024,41(6): 4386.
847-857. [65] 魏春岚,袁长蓉. 肿瘤患者口服化疗药物依从性测量工
[54] PENG D S,HUANG B Q,NING H T,et al. Efficacy and 具的研究进展[J]. 护理学杂志,2014,29(2):89-91.
safety of PI3K/Akt/mTOR inhibitors combined with [66] RESHMA V,CHACKO A M,ABDULLA N,et al. Medi‐
trastuzumab therapy for HER2-positive breast cancer:a cation adherence in cancer patients:a comprehensive re‐
meta-analysis[J]. Eur Rev Med Pharmacol Sci,2022,26 view[J]. Cureus,2024,16(1):e52721.
(20):7667-7678. [67] 魏春岚,袁长蓉. 肿瘤患者口服化疗药物依从性的影响
[55] SHAN W H,WU G X,HUANG Y T,et al. Adverse 因素及干预研究进展[J]. 中国护理管理,2014,14(9):
events in lymphoma patients treated with phosphoinosi- 998-1001.
tide 3 kinase inhibitor in clinical trials:a meta-analysis[J]. [68] AVERY A J,RODGERS S,CANTRILL J A,et al. A
Ann Hematol,2022,101(8):1741-1753. pharmacist-led information technology intervention for
[56] XU H C,WANG Y,HAN Y Q,et al. CDK4/6 inhibitors medication errors (PINCER):a multicentre,cluster ran‐
versus PI3K/AKT/mTOR inhibitors in women with hor‐ domised,controlled trial and cost-effectiveness analysis
mone receptor-positive,HER2-negative metastatic breast [J]. Lancet,2012,379(9823):1310-1319.
cancer:an updated systematic review and network meta- [69] BLUM M R,SALLEVELT B T G M,SPINEWINE A,
analysis of 28 randomized controlled trials[J]. Front On‐ et al. Optimizing therapy to prevent avoidable hospital ad‐
col,2022,12:956464. missions in multimorbid older adults (OPERAM):cluster
[57] LEUNG J H,LEUNG H W C,WANG S Y,et al. Efficacy randomised controlled trial[J]. BMJ,2021,374:n1585.
and safety of CDK4/6 and PI3K/AKT/mTOR inhibitors as [70] 田欣,闫雪莲,梅丹,等. 全国医疗机构药物重整服务规
second-line treatment in postmenopausal patients with hor‐ 范化开展情况的调查研究[J]. 中国药房,2024,35(10):
mone receptor-positive,HER-2-negative metastatic breast 1163-1167.
cancer:a network meta-analysis[J]. Expert Opin Drug Saf, [71] 都丽萍,梅丹,张波,等.用药教育标准制订与解析[J].医
2021,20(8):949-957. 药导报,2022,41(11):1635-1638.
[58] RUGO H S,ANDRÉ F,YAMASHITA T,et al. Time [72] 四川省医学科学院·四川省人民医院药学部,中华医学
course and management of key adverse events during the 会临床药学分会,童荣生,等. 临床药学服务价值评价实
randomized phase Ⅲ SOLAR-1 study of PI3K inhibitor 践指南:第1版[J]. 医药导报,2024,43(3):321-333.
alpelisib plus fulvestrant in patients with HR-positive ad‐ [73] 国家肿瘤质控中心乳腺癌专家委员会,北京乳腺病防治
vanced breast cancer[J]. Ann Oncol,2020,31(8):1001- 学会健康管理专业委员会. 中国乳腺癌随诊随访与健康
1010. 管理指南:2022版[J]. 中华肿瘤杂志,2022,44(1):1-28.
[59] SHEN S,CHEN Y,CARPIO A,et al. Characterization of (收稿日期:2024-12-12 修回日期:2025-04-19)
alpelisib-associated hyperglycemia in metastatic breast (编辑:刘明伟)
cancer[J]. J Clin Oncol,2022,40(Supp. 16):1016.
· 1300 · China Pharmacy 2025 Vol. 36 No. 11 中国药房 2025年第36卷第11期